Nektar Therapeutics (NASDAQ:NKTR) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Nektar Therapeutics (NASDAQ:NKTR) have earned an average rating of “Moderate Buy” from the seven brokerages that are presently covering the stock, MarketBeat reports. Two equities research analysts have rated the stock with a hold recommendation, four have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $4.08.

A number of research analysts recently issued reports on the stock. HC Wainwright restated a “buy” rating and set a $6.50 target price on shares of Nektar Therapeutics in a research report on Monday, January 13th. BTIG Research restated a “buy” rating and set a $4.00 target price on shares of Nektar Therapeutics in a research report on Monday, September 30th. Piper Sandler began coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They set an “overweight” rating and a $7.00 target price for the company. Finally, B. Riley began coverage on shares of Nektar Therapeutics in a research report on Wednesday, January 8th. They issued a “buy” rating and a $4.00 price objective for the company.

Insider Transactions at Nektar Therapeutics

In other news, insider Jonathan Zalevsky sold 51,115 shares of the business’s stock in a transaction dated Thursday, December 19th. The shares were sold at an average price of $0.94, for a total transaction of $48,048.10. Following the completion of the sale, the insider now owns 326,904 shares of the company’s stock, valued at $307,289.76. The trade was a 13.52 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Mark Andrew Wilson sold 33,402 shares of the company’s stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $0.90, for a total transaction of $30,061.80. Following the sale, the insider now directly owns 351,892 shares of the company’s stock, valued at approximately $316,702.80. This represents a 8.67 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 155,575 shares of company stock valued at $149,878 over the last 90 days. Corporate insiders own 3.71% of the company’s stock.

Institutional Trading of Nektar Therapeutics

Several large investors have recently bought and sold shares of the business. Victory Capital Management Inc. purchased a new stake in shares of Nektar Therapeutics in the 2nd quarter valued at approximately $29,000. Valence8 US LP purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $34,000. Intech Investment Management LLC purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $41,000. XTX Topco Ltd purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $46,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at approximately $61,000. Hedge funds and other institutional investors own 75.88% of the company’s stock.

Nektar Therapeutics Price Performance

NASDAQ NKTR opened at $0.89 on Tuesday. The company has a market capitalization of $164.54 million, a PE ratio of -1.06 and a beta of 0.59. The company has a fifty day moving average of $1.04 and a 200 day moving average of $1.20. Nektar Therapeutics has a 1 year low of $0.48 and a 1 year high of $1.93.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.